British Journal of Clinical Pharmacology

Cover image for Vol. 82 Issue 5

Special Issue: Mechanistic target of rapamycin (mTOR): future therapeutic opportunities

November 2016

Volume 82, Issue 5

Pages 1151–1403

  1. ISSUE INFORMATION

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. REVIEW-THEMED ISSUE
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. PHARMACOKINETICS
    10. PHARMACOKINETIC DYNAMIC RELATIONSHIPS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. METHODS IN CLINICAL PHARMACOLOGY
    14. PHARMACOEPIDEMIOLOGY
    15. META-ANALYSIS
    16. LETTER TO THE EDITOR
    1. You have free access to this content
      Issue Information (pages 1151–1153)

      Version of Record online: 12 OCT 2016 | DOI: 10.1111/bcp.12774

  2. ISSUE HIGHLIGHTS

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. REVIEW-THEMED ISSUE
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. PHARMACOKINETICS
    10. PHARMACOKINETIC DYNAMIC RELATIONSHIPS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. METHODS IN CLINICAL PHARMACOLOGY
    14. PHARMACOEPIDEMIOLOGY
    15. META-ANALYSIS
    16. LETTER TO THE EDITOR
    1. You have free access to this content
      Issue Highlights (pages 1154–1155)

      Version of Record online: 12 OCT 2016 | DOI: 10.1111/bcp.13137

  3. EDITORIAL

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. REVIEW-THEMED ISSUE
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. PHARMACOKINETICS
    10. PHARMACOKINETIC DYNAMIC RELATIONSHIPS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. METHODS IN CLINICAL PHARMACOLOGY
    14. PHARMACOEPIDEMIOLOGY
    15. META-ANALYSIS
    16. LETTER TO THE EDITOR
    1. You have free access to this content
  4. REVIEW-THEMED ISSUE

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. REVIEW-THEMED ISSUE
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. PHARMACOKINETICS
    10. PHARMACOKINETIC DYNAMIC RELATIONSHIPS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. METHODS IN CLINICAL PHARMACOLOGY
    14. PHARMACOEPIDEMIOLOGY
    15. META-ANALYSIS
    16. LETTER TO THE EDITOR
    1. You have free access to this content
      New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation (pages 1158–1170)

      Matthias Waldner, Daniel Fantus, Mario Solari and Angus W. Thomson

      Version of Record online: 6 MAR 2016 | DOI: 10.1111/bcp.12893

      • image
    2. You have free access to this content
    3. You have free access to this content
      Therapeutic potential of mTOR inhibitors for targeting cancer stem cells (pages 1180–1188)

      Maria Giovanna Francipane and Eric Lagasse

      Version of Record online: 26 DEC 2015 | DOI: 10.1111/bcp.12844

      • image
    4. You have free access to this content
      The therapeutic potential of mTOR inhibitors in breast cancer (pages 1189–1212)

      Linda S. Steelman, Alberto M. Martelli, Lucio Cocco, Massimo Libra, Ferdinando Nicoletti, Stephen L. Abrams and James A. McCubrey

      Version of Record online: 10 MAY 2016 | DOI: 10.1111/bcp.12958

      • image
      • image
      • image
    5. You have free access to this content
      Targeting mTOR for the treatment of B cell malignancies (pages 1213–1228)

      Jong-Hoon Scott Lee, Thanh-Trang Vo and David A. Fruman

      Version of Record online: 3 MAR 2016 | DOI: 10.1111/bcp.12888

      • image
      • image
      • image
      • image
    6. You have full text access to this OnlineOpen article
    7. You have free access to this content
    8. You have free access to this content
      Potential therapeutic effects of mTOR inhibition in atherosclerosis (pages 1267–1279)

      Ammar Kurdi, Guido R. Y. De Meyer and Wim Martinet

      Version of Record online: 29 DEC 2015 | DOI: 10.1111/bcp.12820

      • image
      • image
      • image
    9. You have free access to this content
      New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs (pages 1280–1290)

      Zuleide M. Ignácio, Gislaine Z. Réus, Camila O. Arent, Helena M. Abelaira, Meagan R. Pitcher and João Quevedo

      Version of Record online: 8 JAN 2016 | DOI: 10.1111/bcp.12845

      • image
      • image
  5. SYSTEMATIC REVIEW

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. REVIEW-THEMED ISSUE
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. PHARMACOKINETICS
    10. PHARMACOKINETIC DYNAMIC RELATIONSHIPS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. METHODS IN CLINICAL PHARMACOLOGY
    14. PHARMACOEPIDEMIOLOGY
    15. META-ANALYSIS
    16. LETTER TO THE EDITOR
  6. REVIEWS

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. REVIEW-THEMED ISSUE
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. PHARMACOKINETICS
    10. PHARMACOKINETIC DYNAMIC RELATIONSHIPS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. METHODS IN CLINICAL PHARMACOLOGY
    14. PHARMACOEPIDEMIOLOGY
    15. META-ANALYSIS
    16. LETTER TO THE EDITOR
    1. You have free access to this content
  7. CLINICAL TRIALS

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. REVIEW-THEMED ISSUE
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. PHARMACOKINETICS
    10. PHARMACOKINETIC DYNAMIC RELATIONSHIPS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. METHODS IN CLINICAL PHARMACOLOGY
    14. PHARMACOEPIDEMIOLOGY
    15. META-ANALYSIS
    16. LETTER TO THE EDITOR
    1. You have full text access to this OnlineOpen article
      First-in-human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males (pages 1315–1324)

      Viktoria Moschetti, Katja Boland, Ulrich Feifel, Anja Hoch, Heike Zimdahl-Gelling and Michael Sand

      Version of Record online: 22 AUG 2016 | DOI: 10.1111/bcp.13060

      • image
      • image
      • image
      • image
  8. PHARMACOKINETICS

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. REVIEW-THEMED ISSUE
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. PHARMACOKINETICS
    10. PHARMACOKINETIC DYNAMIC RELATIONSHIPS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. METHODS IN CLINICAL PHARMACOLOGY
    14. PHARMACOEPIDEMIOLOGY
    15. META-ANALYSIS
    16. LETTER TO THE EDITOR
    1. Drug disposition before and after gastric bypass: fenofibrate and posaconazole (pages 1325–1332)

      Ina Gesquiere, Bart Hens, Bart Van der Schueren, Raf Mols, Jan de Hoon, Matthias Lannoo, Christophe Matthys, Veerle Foulon and Patrick Augustijns

      Version of Record online: 25 JUL 2016 | DOI: 10.1111/bcp.13054

      • image
      • image
  9. PHARMACOKINETIC DYNAMIC RELATIONSHIPS

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. REVIEW-THEMED ISSUE
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. PHARMACOKINETICS
    10. PHARMACOKINETIC DYNAMIC RELATIONSHIPS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. METHODS IN CLINICAL PHARMACOLOGY
    14. PHARMACOEPIDEMIOLOGY
    15. META-ANALYSIS
    16. LETTER TO THE EDITOR
    1. Population PK–PD analyses of CD25 occupancy, CD56bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis (pages 1333–1342)

      Lei Diao, Yaming Hang, Ahmed A. Othman, Devangi Mehta, Lakshmi Amaravadi, Ivan Nestorov and Jonathan Q. Tran

      Version of Record online: 3 AUG 2016 | DOI: 10.1111/bcp.13051

      • image
      • image
      • image
  10. DRUG INTERACTIONS

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. REVIEW-THEMED ISSUE
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. PHARMACOKINETICS
    10. PHARMACOKINETIC DYNAMIC RELATIONSHIPS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. METHODS IN CLINICAL PHARMACOLOGY
    14. PHARMACOEPIDEMIOLOGY
    15. META-ANALYSIS
    16. LETTER TO THE EDITOR
    1. Abciximab as a bridging strategy to overcome morphine–prasugrel interaction in STEMI patients (pages 1343–1350)

      Jolanta M. Siller-Matula, Simon Specht, Jacek Kubica, Dimitrios Alexopoulos, Raffaele De Caterina, Eva-Luise Hobl, Bernd Jilma, Günter Christ and Irene M. Lang

      Version of Record online: 24 JUL 2016 | DOI: 10.1111/bcp.13053

      • image
      • image
      • image
      • image
      • image
  11. THERAPEUTICS

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. REVIEW-THEMED ISSUE
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. PHARMACOKINETICS
    10. PHARMACOKINETIC DYNAMIC RELATIONSHIPS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. METHODS IN CLINICAL PHARMACOLOGY
    14. PHARMACOEPIDEMIOLOGY
    15. META-ANALYSIS
    16. LETTER TO THE EDITOR
    1. You have full text access to this OnlineOpen article
    2. Delays during the administration of acetylcysteine for the treatment of paracetamol overdose (pages 1358–1363)

      George P. Bailey, Javad Najafi, Muhammad E. M. O. Elamin, W. Stephen Waring, Simon H. L. Thomas, John R. H. Archer, David M. Wood and Paul I. Dargan

      Version of Record online: 10 AUG 2016 | DOI: 10.1111/bcp.13063

      • image
  12. METHODS IN CLINICAL PHARMACOLOGY

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. REVIEW-THEMED ISSUE
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. PHARMACOKINETICS
    10. PHARMACOKINETIC DYNAMIC RELATIONSHIPS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. METHODS IN CLINICAL PHARMACOLOGY
    14. PHARMACOEPIDEMIOLOGY
    15. META-ANALYSIS
    16. LETTER TO THE EDITOR
    1. Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy (pages 1364–1370)

      Mahesh N. Samtani, Partha Nandy, Paulien Ravenstijn, Bart Remmerie, An Vermeulen, Alberto Russu, Peter D'hoore, Ellen Z. Baum, Adam Savitz, Srihari Gopal and David Hough

      Version of Record online: 24 JUL 2016 | DOI: 10.1111/bcp.13050

      • image
      • image
      • image
    2. Inflammation induced by inhaled lipopolysaccharide depends on particle size in healthy volunteers (pages 1371–1381)

      Virginie Doyen, Gabrielle Pilcer, Phong Huy Duc Dinh, Francis Corazza, Alfred Bernard, Pierre Bergmann, Nicolas Lefevre, Karim Amighi and Olivier Michel

      Version of Record online: 28 JUL 2016 | DOI: 10.1111/bcp.13052

      • image
      • image
      • image
      • image
      • image
  13. PHARMACOEPIDEMIOLOGY

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. REVIEW-THEMED ISSUE
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. PHARMACOKINETICS
    10. PHARMACOKINETIC DYNAMIC RELATIONSHIPS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. METHODS IN CLINICAL PHARMACOLOGY
    14. PHARMACOEPIDEMIOLOGY
    15. META-ANALYSIS
    16. LETTER TO THE EDITOR
    1. Too many, too few, or too unsafe? Impact of inappropriate prescribing on mortality, and hospitalization in a cohort of community-dwelling oldest old (pages 1382–1392)

      Maarten Wauters, Monique Elseviers, Bert Vaes, Jan Degryse, Olivia Dalleur, Robert Vander Stichele, Thierry Christiaens and Majda Azermai

      Version of Record online: 3 AUG 2016 | DOI: 10.1111/bcp.13055

      • image
      • image
  14. META-ANALYSIS

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. REVIEW-THEMED ISSUE
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. PHARMACOKINETICS
    10. PHARMACOKINETIC DYNAMIC RELATIONSHIPS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. METHODS IN CLINICAL PHARMACOLOGY
    14. PHARMACOEPIDEMIOLOGY
    15. META-ANALYSIS
    16. LETTER TO THE EDITOR
    1. Zinc acetate lozenges for treating the common cold: an individual patient data meta-analysis (pages 1393–1398)

      Harri Hemilä, Edward J. Petrus, James T. Fitzgerald and Ananda Prasad

      Version of Record online: 28 JUL 2016 | DOI: 10.1111/bcp.13057

  15. LETTER TO THE EDITOR

    1. Top of page
    2. ISSUE INFORMATION
    3. ISSUE HIGHLIGHTS
    4. EDITORIAL
    5. REVIEW-THEMED ISSUE
    6. SYSTEMATIC REVIEW
    7. REVIEWS
    8. CLINICAL TRIALS
    9. PHARMACOKINETICS
    10. PHARMACOKINETIC DYNAMIC RELATIONSHIPS
    11. DRUG INTERACTIONS
    12. THERAPEUTICS
    13. METHODS IN CLINICAL PHARMACOLOGY
    14. PHARMACOEPIDEMIOLOGY
    15. META-ANALYSIS
    16. LETTER TO THE EDITOR
    1. NSAID-induced symptomatic hypophosphataemia (pages 1399–1401)

      Morten Sommerfeldt Skeid, Ulrik Pedersen-Bjergaard, Peter Lommer Kristensen and Lisbet Brandi

      Version of Record online: 10 AUG 2016 | DOI: 10.1111/bcp.13061

SEARCH

SEARCH BY CITATION